EUCTR2009-017594-37-FI进行中（未招募）不适用
A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •6 - 17 years with MSSBP>/= 95th percentile for age, gender and height.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) AST/ALT > 3xULN
- •2) Bilirubin > 2xULN
- •3) eGFR < 30ml/min/1.73m2
- •4) Patients using RAAS blockers after screening
研究者
相似试验
进行中（未招募）
不适用
Evaluation of long-term safety and tolerability in children 6 to 17 years of age who have high blood pressure.EUCTR2009-017594-37-DEovartis Pharma Services AG150
进行中（未招募）
不适用
Evaluation of long-term safety and tolerability in children 6 to 17 years of age who have high blood pressure.Hypertension.EUCTR2009-017594-37-PLovartis Pharma Services AG155
进行中（未招募）
不适用
A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depressioMultiple SclerosisDepressionMedDRA version: 14.1Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-001692-39-DEovartis Pharma GmbH
进行中（未招募）
不适用
A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladderTreatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.MedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2008-004124-23-GBPfizer Limited326
已完成
不适用
Diabetes and EyeCTRI/2018/05/014060ovartis Healthcare Pvt Ltd30